Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Net Interest Income

Last Annual Value

4.15M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Net Interest Income

PRME · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.15M
N/AN/AN/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
13.81M
-14.5%485.9%N/A
25.26M
24.2%99.9%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
19.53M
91.4%N/AN/A
11.75M
27.3%N/A62.6%
13.23M
31.3%N/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
5.48M
9.2%N/AN/A
-3.05M
N/AN/AN/A
0.00
N/AN/AN/A
40.24M
-22.7%146.9%N/A
17.87M
138.7%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14